Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

por Falkenius, Johan, Johansson, Hemming, Tuominen, Rainer, Frostvik Stolt, Marianne, Hansson, Johan, Egyhazi Brage, Suzanne
Publicado 2017

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study

por Helgadottir, Hildur, Ny, Lars, Ullenhag, Gustav J, Falkenius, Johan, Mikiver, Rasmus, Olofsson Bagge, Roger, Isaksson, Karolin
Publicado 2023